[Federal Register Volume 77, Number 222 (Friday, November 16, 2012)]
[Notices]
[Pages 68783-68784]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-27897]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Prospective Grant of Exclusive License: Veterinary Vaccines for
Rift Valley Fever Virus
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37
CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for
Disease Control and Prevention (CDC), Department of Health and Human
Services (HHS), is thinking of giving a co-exclusive license in Africa,
and an exclusive license in all territories other than Africa, in the
field of use of veterinary vaccines, to practice the inventions listed
in the patent applications referred to below to Merial Limited, having
a place of business in Duluth, Georgia. The patent rights in these
inventions have been assigned to the government of the United States of
America. The patent application(s) to be licensed are:
US Provisional Application 61/016,065, filed 12/21/2007,
entitled ``Development of Rift Valley Fever Virus Utilizing Reverse
Genetics,'' US Provisional Application 61/
[[Page 68784]]
042,987, filed 4/7/2008, entitled ``Recombinant Rift Valley Fever
(RVF) Viruses and Method of Use,'' PCT Application PCT/US2008/
087023, filed 12/16/2008, entitled ``Recombinant Rift Valley Fever
(RVF) Viruses and Method of Use,'' US National Stage Application 12/
809,561, filed 6/18/2010, entitled ``Recombinant Rift Valley Fever
(RVF) Viruses and Methods of Use,'' and all related continuing and
foreign patents/patent applications for the technology family. CDC
Technology ID No. I-008-08.
Status: Pending.
Priority Date(s):
61/042,987 4/7/2008.
61/016,065 12/21/2007.
The planned co-exclusive license and exclusive license will be
royalty-bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7.
Technology: The technology allows for the generation of precisely
defined attenuated vaccine constructs that contain complete deletions
of critical virulence factors of Rift Valley Fever (RVF) virus. These
attenuated vaccines constructs still have the ability to induce robust
protective immunity following the administration of a single vaccine
dose in a rat model of lethal disease. The vaccines can protect
immunized animals against virulent virus challenge. The vaccine
candidates also allow for the differentiation of naturally infected and
vaccinated animals--a feature that is critical in agricultural
settings. This approach will allow for the rapid generation of
effective, safe RVF vaccine candidates to control and prevent the
spread of wild-type RVF virus in a variety of settings, including
preventing the infection of humans or animals during endemic, epidemic
or epizootic situations in affected countries, or for prophylactic use
among humans in high risk occupational settings, or following
intentional release of RVF virus during bioterrorism.
DATES: Only written comments and/or applications for a license which
are received by CDC on or before December 17, 2012 will be considered.
ADDRESSES: Requests for a copy of these patent applications, inquiries,
comments, and other materials relating to the planned license should be
directed to Donald Prather, J.D., Ph.D., Technology Licensing and
Marketing Specialist, Technology Transfer Office, Centers for Disease
Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79,
Atlanta, GA 30341, Telephone: (770) 488-8612; Facsimile: (770) 488-
8615; Email: [email protected].
SUPPLEMENTARY INFORMATION: Applications for a license filed in response
to this notice will be treated as objections to giving the planned
license.
Comments and objections submitted in response to this notice will
not be made available for public inspection, and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: November 8, 2012.
J. Ronald Campbell,
Director, Division of Executive Secretariat, Centers for Disease
Control and Prevention.
[FR Doc. 2012-27897 Filed 11-15-12; 8:45 am]
BILLING CODE 4163-18-P